Sirtuin 3 regulates astrocyte activation by reducing Notch1 signaling after status epilepticus

Sirtuin3 (Sirt3) is a nicotinamide adenine dinucleotide enzyme that contributes to aging, cancer, and neurodegenerative diseases. Recent studies have reported that Sirt3 exerts anti-inflammatory effects in several neuropathophysiological disorders. As epilepsy is a common neurological disease, in the present study, we investigated the role of Sirt3 in astrocyte activation and inflammatory processes after epileptic seizures. We found the elevated expression of Sirt3 within reactive astrocytes as well as in the surrounding cells in the hippocampus of patients with temporal lobe epilepsy and a mouse model of pilocarpine-induced status epilepticus (SE). The upregulation of Sirt3 by treatment with adjudin, a potential Sirt3 activator, alleviated SE-induced astrocyte activation; whereas, Sirt3 deficiency exacerbated astrocyte activation in the hippocampus after SE. In addition, our results showed that Sirt3 upregulation attenuated the activation of Notch1 signaling, nuclear factor kappa B (NF-kappa B) activity, and the production of interleukin-1 beta (IL1 beta) in the hippocampus after SE. By contrast, Sirt3 deficiency enhanced the activity of Notch1/NF-kappa B signaling and the production of IL1 beta. These findings suggest that Sirt3 regulates astrocyte activation by affecting the Notch1/NF-kappa B signaling pathway, which contributes to the inflammatory response after SE. Therefore, therapies targeting Sirt3 may be a worthy direction for limiting inflammatory responses following epileptic brain injury. Sirt3 expression was elevated in activated astrocytes after SE. Sirt3 regulates astrocyte activation by affecting the Notch1/NF-kappa B signaling pathway, which contributes to the inflammatory response after SE. image